HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth

Signup
Browse Studies

City:   Chicago
State:   Illinois
Zip Code:   60614
Conditions:   Patient Adherence - HIV
Purpose:   The purpose of the proposed study is to test SMS (short message service) text messaging technology to improve medication adherence among youth living with HIV (YLH). The proposed study is a randomized controlled trial of the effect of text message reminders on ART (anti-retroviral therapy) adherence among non-adherent YLH. Daily text message reminders will be sent to patients randomized to the intervention group according to their medication schedule, for 6 months. The investigators will enroll 152 non-adherent YLH, ages 16-29. Half of the sample (N=76), randomized to the intervention, will receive daily SMS text message medication reminders and half will be randomized to the control condition (N=76) and receive standard of care (SOC) only. For the controlled trial, adherence levels and viral load will be collected at baseline, 3-month and 6-month follow-up. In addition, at the end of the initial 6-month enrollment period, participants in the control condition will cross-over to the SMS intervention and participants in the intervention condition will cease to receive the SMS intervention. Adherence and viral load data will be collected from each group at 9- and 12-month follow-up points. The investigators hypothesize that youth in the intervention condition will demonstrate a clinically meaningful increase in adherence at 3 and 6 months post-baseline, from approximately 70% to 90% adherence to ART.
Study Summary:   The purpose of the proposed study is to test an intervention using SMS text messaging technology to improve medication adherence among YLH. The proposed study is a randomized controlled trial of the effect of text message reminders on ART adherence rates among non-adherent YLH. Daily text message reminders will be sent to all patients randomized to the intervention group according to their medication schedule, for six months. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the study period. The investigators will enroll 152 YLH, ages 16-29 (i.e., perinatally, transfusion, or behaviorally acquired -- consistent with our feasibility study and the distribution of infection mode in the primary clinic sites) who have demonstrated poor adherence to ART. Half of the sample (N=76), randomized to the intervention, will receive daily short message service (SMS; aka "text message") medication reminders and half will be randomized to the control condition (N=76) and receive standard of care (SOC) only. For the controlled trial, adherence levels and viral load will be collected at baseline, 3-month and 6-month follow-up. In addition, at the end of the initial 6-month enrollment period, participants in the control condition will cross-over to the SMS intervention for 6 months and participants in the intervention condition will cease to receive the SMS intervention. Adherence and viral load data will be collected from each group at the 9-month and 12-month follow-up points. The advantages of these additional features are that they allow the investigators to offer the intervention to all participants, to evaluate the intervention effect in the control group (to confirm the intervention effect) and to assess sustained intervention effects in the intervention group (post-intervention). Specific Aims: 1. To determine the efficacy of an SMS text messaging intervention on our primary outcome: adherence to ART among poorly adherent YLH, ages 16-29 (a group shown to be at high risk for substance use) over a 6-month intervention period, with effects assessed at 3 and 6-months post-baseline. 2. To explore the efficacy of an SMS text messaging intervention on a secondary, exploratory outcome: viral load and CD4 counts, over a 6-month intervention period, with effects assessed at 3 and 6-months post-baseline. 3. To assess the feasibility, acceptability, and satisfaction of this intervention and clinical trial approach by both objective (e.g., automated message delivery and response counts) and subjective measures (e.g., reported satisfaction, acceptability). Primary Hypotheses: 1. Youth randomized to the SMS text messaging intervention will show greater improvements in levels of adherence to ART and secondary outcomes during the intervention period at 3 and 6 months post-baseline, in comparison to those receiving standard of care only. The investigators hypothesize at least a 10-point difference in adherence level between groups at 3 and 6 months for the intervention to be clinically meaningful. 2. Youth randomized to SMS text messaging intervention will maintain improvements in adherence (i.e., > 90% adherence) at 9-month and 12-month follow-ups.
Criteria:   Inclusion Criteria: - Diagnosed with HIV infection (perinatally, transfusion, or behaviorally acquired; documented by medical record review or verification from referring professional) - Have cell phone access - Report regular use of text messaging technology - 16 to 29 years old - English-speaking - On an ART regimen for at least one month at the time of enrollment (i.e., not new to ART) with poor adherence to their antiretroviral regimen. For the purposes of this study, poor adherence will be defined at screening by one or more of the following: a) per the AIDS Clinical Trials Group (ACTG) screening questionnaire, participant reports missing at least one dose in the last week or b) reports missing more than 3 medication doses in the last month. Exclusion Criteria: - Do not report regular follow-up with their physician (at least every 3 months) - Pregnant and on ART only due to pregnancy (i.e., will no longer be prescribed ART after delivery) - Unable to provide assent or consent.
NCT ID:   NCT01354210
Primary Contact:   Principal Investigator
Robert Garofalo, MD, MPH
Children's Memorial Hospital

Lisa Kuhns, PhD, MPH
Phone: 773-880-8325
Email: txtxt@childrensmemorial.org
Backup Contact:   Email: txtxt@childrensmemorial.org
Camdin Gray, BS
Phone: 773-880-3919
Location Contact:   Chicago, Illinois 60614
United States



There is no listed contact information for this specific location.

Site Status: Recruiting

Click here to see:
  • Clinical trials for HIV in Chicago, Illinois

Data Source:   ClinicalTrials.gov
Date Processed:   May 18, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"
First Name:  
Last Name:  
Email Address:  
Confirm Email:    
Daytime Phone (eg. 555-555-5555):  
City:  
State:
Zip Code:    
Best Time to Call:  
Questions/Comments:  
  • NEARBY STUDIES

Within 25 Miles

Irritable Bowel Syndrome (Diarrhea) - Chicago IL

Chronic Obstructive Pulmonary Disease (COPD) - Chicago IL

Asthma - Chicago IL

Irritable Bowel Syndrome - Chicago IL

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Addison IL

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Chicago IL

Crohn's Disease - Oak Lawn IL

Crohn's Disease - Arlington Heights IL

Post Herpetic Neuralgia (PHN) - Chicago IL

Excessive Daytime Sleepiness with Narcolepsy - Chicago IL

Postherpetic Neuralgia (Post-shingles pain) - Chicago IL

Urinary Tract Infection - Evanston IL

Type 2 Diabetes - Evanston IL

Low Back Pain and Constipation - Chicago IL

Anti-Depressant Induced Sexual Dysfunction - Chicago IL

Postherpetic Neuralgia (Post-shingles pain) - Chicago IL

Uncontrolled Angina (Adult Stem Cell Research) - Chicago IL

Uncontrolled Angina (Adult Stem Cell Research) - Chicago IL

Dry Eye - Hoffman Estates IL

COPD (Emphysema and Chronic Bronchitis) - Skokie IL

COPD (Emphysema and Chronic Bronchitis) - River Forest IL

Within 50 Miles

Bipolar Disorder - Libertyville IL

ADHD in Teens (Ages 13-17)- Libertyville IL

Pediatric Depression - Naperville IL

Depression - Libertyville IL

Arthritis - Valparaiso IN

Gout - Gurnee IL

Chronic Low Back Pain - Gurnee IL

Multiple Sclerosis - Flossmoor IL

Low Back Pain and Constipation - Chesterton IN

Anti-Depressant Induced Sexual Dysfunction - Joliet IL

Osteoarthritis of the Knee - Kenosha WI

Within 100 Miles

Crohn's Disease - Milwaukee WI

Pediatric Depression - Milwaukee WI

Irritable Bowel Syndrome - Bourbonnais IL

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Rockford IL

Arthritis - La Porte IN

Gout - La Porte IN

Healthy Volunteers (Ages 10-25) - Mishawaka IN

Irritable Bowel Syndrome (with diarrhea) - Stevensville MI

Irritable Bowel Syndrome (with diarrhea) - Milwaukee WI

Gout - Milwaukee WI

Anti-Depressant Induced Sexual Dysfunction - Waukesha WI

Irritable Bowel Syndrome - Milwaukee WI

Uncontrolled Angina (Adult Stem Cell Research) - Milwaukee WI

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.